{
  "id": 6315640,
  "title": "Oppenheimer raises Pharvaris stock price target on trial results",
  "url": "https://urgent.news/2026/09/08/oppenheimer-raises-pharvaris-stock-price-target-on-trial-results",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-08T19:34:43.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/oppenheimer-raises-pharvaris-stock-price-target-on-trial-results-93CH-4892288"
  },
  "original_language": "en",
  "account": null,
  "summary": "Oppenheimer has raised its price target on Pharvaris B.V. (NASDAQ:PHVS) to $75 from $50 following positive clinical trial data, maintaining an Outperform rating. The decision comes after Pharvaris reported efficacy results from the pivotal CHAPTER-3 study of deucrictibant XR in hereditary angioedema prophylaxis, which matched previously reported Phase 2 results and those of market-leading injectable Takhzyro. The analyst firm believes the results put deucrictibant XR ahead of Orladeyo, a marketed treatment, and positions Pharvaris as an emerging leader in treating hereditary and other forms of angioedema. The stock has delivered a 61% return over the past year, and the new price target reflects improved assumptions for probability of success and penetration rate.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}